An Innovator in Cancer Research and Development


Posted by LLJ43 | Posted in Innovator | Posted on 19-01-2017

Clay Siegall co-founded Seattle Genetics in 1998. Clay Siegall is the President, CEO, and Chairman of the Board of the company. He built a company that concentrates its efforts on an investigative examination of the scientific process through research and development in pharmaceuticals while always maintain top of the line patient care and satisfaction. Seattle Genetics is a biotech company that is known around the world for its research in cancer related medication research and development. Under his supervision, Clay Siegall assisted Seattle Genetics to become one of the international leaders in antibody drug conjugate research and develop. They secured FDA approval in 2011 for the drug which is a major accomplishment in cancer research. Clay Siegall has also been a part of the integral plan to make this technology very profitable for the company. This technology is now used in over 60 countries.

Before founding Seattle Genetics, Clay Siegall was deeply invested in institutes that focused on cancer research. From these opportunities Siegall gained invaluable insight into the world of cancer research and development. These experiences and opportunities allowed him to build such a successful and innovative company in Seattle Genetics.Clay Siegall has a PhD in Genetics from George Washington University. He also received a BS in Zoology at the University of Maryland. Dr. Siegall had position at several organizations and institutions before beginning his career with Seattle Genetics including the National Institute of Health, the Bristol-Myers, the National Cancer Institute, and Squibb Pharmaceutical Research Institute. He has received numerous recognitions and accolades throughout his career. He has obtained over 15 patients and 70 publications. His is a well-respected member of the cancer research community and serves currently serves on the Board of Directors for various companies.